Strata Critical Medical, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Earnings per Common Share (Tables)

Earnings per Common Share (Tables)

3 Months Ended

Mar. 31, 2026

Summary of Reconciliation of Net Income (Loss) and Common Stock Share Amounts

A reconciliation of net income (loss) and common share amounts used in the computation of basic and diluted income (loss) per common share is presented below.


	Three Months Ended March 31,
		2026		2025











Numerator:
Net income (loss) from continuing operations		$	2,402	$	(1,612)
Net loss from discontinued operations		(248)		(1,881)
Net income (loss)		$	2,154	$	(3,493)









Denominator:
Weighted-average number of common shares (basic)		85,322,941		79,891,829
Effect of dilutive securities:
Options to purchase shares of common stock		2,507,734		—
Restricted shares of common stock		2,338,178		—
Total effect of dilutive securities		4,845,912		—
Weighted-average number of common shares (diluted)		90,168,853		79,891,829

Basic earnings (loss) per share
Continuing operations		$	0.03	$	(0.02)
Discontinued operations		—		(0.02)
Total basic earnings (loss) per share		$	0.03	$	(0.04)

Diluted earnings (loss) per share
Continuing operations		$	0.03	$	(0.02)
Discontinued operations		—		(0.02)
Total diluted earnings (loss) per share		$	0.03	$	(0.04)

Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three months ended March 31, 2026. For the three months ended March 31, 2025, all potentially dilutive securities shown below were excluded from the computation of diluted loss per share as the Company was in a net loss position and their inclusion would have been anti-dilutive.


	Three Months Ended March 31,
		2026	2025


Warrants to purchase shares of common stock (1)		14,166,644	14,166,644
Options to purchase shares of common stock		—	3,556,349
Outstanding shares in escrow (2)		1,041,969	—
Restricted shares of common stock (3)		8,869,832	10,879,863
Total potentially dilutive securities		24,078,445	28,602,856

(1) Warrants are excluded because the effect of their inclusion would be anti-dilutive as their exercise price exceeds the average market price of the Company’s common stock.

(2) 1,041,969 shares remaining in escrow to cover potential indemnification obligations for breaches of general representations and warranties under the Keystone Purchase Agreement. These shares are legally issued and outstanding but are excluded from the weighted average shares outstanding calculation as they are contingently returnable pending expiration of the representations and warranties survival period in September 2026.

(3) Contingently issuable pending satisfaction of the applicable vesting and performance conditions, consisting of 5,918,814 shares related to officer, employee and vendor PSUs and 2,950,219 shares related to Earn-out PSUs and time-based awards granted to the Company's former Chief Executive Officer. 799 shares excluded as their inclusion would be anti-dilutive under the treasury stock method.